Association of NOTCH1 mutation status with early treatment response in 157 children with T-ALL
. | NOTCH1 mutation . | . | . | . | . | . | . | |
|---|---|---|---|---|---|---|---|---|
. | Positive, no. (%) . | Negative, no. (%) . | P* . | Univariate RR (95% CI) . | P* . | Multivariate RR†(95% CI) . | P* . | |
| Prednisone response‡ | .001 | .001 | .028 | |||||
| Good | 57 (69.5) | 31 (41.3) | 1.00§ | 1.00§ | ||||
| Poor | 24 (29.3) | 39 (52.0) | 0.33 (0.17-0.65) | 0.42 (0.19-0.91) | ||||
| Unknown | 1 (1.2) | 5 (6.7) | — | — | ||||
| MRD on day 33 | .019 | .021 | .061 | |||||
| Favorable, less than 10-4 | 30 (36.6) | 14 (18.7) | 1.00§ | 1.00§ | ||||
| Unfavorable, 10-4 or more | 47 (57.3) | 53 (70.7) | 0.41 (0.20-0.87) | 0.45 (0.20-1.04) | ||||
| Not done | 5 (6.1) | 8 (10.7) | — | — | ||||
| MRD on day 78 | .001 | .001 | .009 | |||||
| Favorable, less than 10-4 | 56 (68.3) | 28 (37.3) | 1.00§ | 1.00§ | ||||
| Unfavorable, 10-4 or more | 20 (24.4) | 38 (50.7) | 0.26 (0.13-0.53) | 0.35 (0.16-0.77) | ||||
| Not done | 6 (7.3) | 9 (12.0) | — | — | ||||
. | NOTCH1 mutation . | . | . | . | . | . | . | |
|---|---|---|---|---|---|---|---|---|
. | Positive, no. (%) . | Negative, no. (%) . | P* . | Univariate RR (95% CI) . | P* . | Multivariate RR†(95% CI) . | P* . | |
| Prednisone response‡ | .001 | .001 | .028 | |||||
| Good | 57 (69.5) | 31 (41.3) | 1.00§ | 1.00§ | ||||
| Poor | 24 (29.3) | 39 (52.0) | 0.33 (0.17-0.65) | 0.42 (0.19-0.91) | ||||
| Unknown | 1 (1.2) | 5 (6.7) | — | — | ||||
| MRD on day 33 | .019 | .021 | .061 | |||||
| Favorable, less than 10-4 | 30 (36.6) | 14 (18.7) | 1.00§ | 1.00§ | ||||
| Unfavorable, 10-4 or more | 47 (57.3) | 53 (70.7) | 0.41 (0.20-0.87) | 0.45 (0.20-1.04) | ||||
| Not done | 5 (6.1) | 8 (10.7) | — | — | ||||
| MRD on day 78 | .001 | .001 | .009 | |||||
| Favorable, less than 10-4 | 56 (68.3) | 28 (37.3) | 1.00§ | 1.00§ | ||||
| Unfavorable, 10-4 or more | 20 (24.4) | 38 (50.7) | 0.26 (0.13-0.53) | 0.35 (0.16-0.77) | ||||
| Not done | 6 (7.3) | 9 (12.0) | — | — | ||||
For NOTCH1 mutation-positive patients, n = 82; for NOTCH1 mutation-negative patients, n = 75.
RR indicates relative risk; CI, confidence interval; MRD, minimal residual disease; and —, not applicable.
P χ2 test.
Adjusted for sex, age at diagnosis (categorical; see Table 1), presenting white blood cell count (categorical; see Table 1), and immunophenotype.
Good indicates fewer than 1000 leukemic blood blasts/μL on treatment day 8; poor, more than 1000/μL.
Reference category.